New and Emerging Directions in Myelofibrosis Treatment: Seeking to Improve Quality of Life and Prolong Survival

JAK inhibitors are considered standard therapy for the treatment of symptomatic MF. While ruxolitinib has been the only available JAK inhibitor for this indication for nearly a decade, the more recent approval of fedratinib and pacritinib for front-line MF has broadened treatment options for these patients. 

In this activity, a panel of myelofibrosis experts provide an overview of key data presented at ASH. Led by Dr. Verstovsek, our faculty will offer insights on new agents, new mechanisms of action for the treatment of myelofibrosis associated anemia, and provide perspectives on the future role of “add-on” therapies.